HIV Infection in Pregnancy Francis J. Ndowa WHO RHR/STI FJN_STI_2005 Department of reproductive health and research Département santé et recherche génésiques
Session outline Effect of pregnancy on HIV infection Effect of HIV on pregnancy Effect of maternal HIV on pregnancy outcome Prevention interventions for MTCT
The burden of HIV in pregnancy People living with HIV/AIDS globally (2004).40 million Pregnant women living with HIV/AIDS.1 million New HIV infections in 2004..5 million Newborn infected each day. c. 1600
Effect of pregnancy on HIV HIV-positive women do not seem to have a worse prognosis from HIV on account of becoming pregnant Short-course treatments to prevent infection of a newborn are not the best choice for the mother s health Medications taken only during labour and delivery may precipitate resistance to future treatment options for the mother Combination therapies are the standard treatment
Burden of HIV in pregnancy HIV prevalence among pregnant women in South Africa, 1990 to 1999 25 22.8 22.4 HIV prevalence (%) 20 15 10 7.6 10.4 14.2 17 5 4 1.7 2.1 0.7 0 90 91 92 93 94 95 96 97 98 99 00001-E-13 27 June 2000 Source: Department of Health, South Africa
Consequences on Pregnancy
Complications of pregnancy and delivery found among HIV positive (mainly symptomatic) women compared to HIV negative women: 1990-99 More frequent and severe reproductive tract infections More severe and more frequent blood loss, sepsis and delayed wound healing after caesarean section, and induced abortion Lower fertility rate ratios Insufficient weight gain in pregnancy
Complications of pregnancy and delivery found among HIV positive (mainly symptomatic) women compared to HIV negative women: 1990-99 Higher rates of ectopic pregnancy Greater risk of post-partum haemorrhage and post-partum sepsis More frequent and severe anaemia and malaria, and possibly tuberculosis. Complications of AIDS-related conditions, such as bacterial pneumonia
Consequences on The Newborn
Consequences on Pregnancy Possible Outcome Transmissible Infections Spontaneous abortion Ectopic pregnancy Anaemia Premature rupture of membranes Prematurity & Low birthweight Stillbirth Post-partum infection Malaria TB Syphilis HIV/AIDS Gonorrhea / Chlamydia Bacterial vaginosis
Consequences on the newborn Transmissible Infections Malaria Tuberculosis Syphilis HIV/AIDS Gonorrhea Chlamydia Hepatitis B Herpes simplex virus Transmission & Possible Effects for the Infant Congenital malaria Rarely congenital tuberculosis Transmitted during breast feeding Congenital syphilis (in approx. 1/3 of cases). Can result in infant death or long-term illness Transmitted during pregnancy Transmission can occur during pregnancy, delivery, and through breastfeeding in up to 30-40% of infected mothers Paediatric AIDS. Causes long-term illness and death. Half of infected infants die within their first 36 months. Opthalmia neonatorum. Can result in blindness Infection occurs during delivery through birth canal Ocular prophylaxis (eye-drops given to newborn within one hour of birth) can prevent Ophthalmia neonatorum Ophthalmia neonatorum Neonatal pneumonia Possible transmission during pregnancy Congenital herpes. Affects nervous system and can cause death Transmitted during pregnancy and through exposure during delivery
The variable risk of MTCT of HIV (with and without preventive interventions no ARV, prolonged breastfeeding ARV, prolonged breastfeeding no ARV, no breastfeeding ARV, no breastfeeding ARV, no breastfeeding, C-section Infected Uninfected 0% 25% 50% 75% 100%
Prevention of MTCT through antiretrovirals
Prevention of MTCT through antiretrovirals Mechanisms of action: Maternal component Reduce viral load in mother's blood, genital fluids (and milk) during pregnancy, delivery (and breastfeeding) Infant regimen: Acts as a post-exposure prophylaxis (viral particles transmitted during birth are eliminated
ARV Use and HIV Transmission (WITS, USA) % receiving therapy 100 80 60 40 20 22.7 HAART Multi-ART ZDV Prophylaxis ZDV Monotherapy Transmission (%) 21.4 19.8 24.5 9.1 10.7 3.4 3.6 3.1 3.3 40 20 0 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 Source: Blattner, Durban 2000, LbOr4
Antenatal Antiretroviral Treatment and Perinatal Transmission in WITS, 1990-1999 1999 30 Blattner W. XIII AIDS Conf, July 2000, Durban S Africa (LBOr4) % Transmission 20 10 0 21% None (N=391) Type ARV vs None p value: 19% ZDV Mono (<4/94) (N=206) 8% ZDV Mono (>4/94) (N=529) 4% Multi- ART (N=179) 1% HAART (N=187) 0.76 <0.01 <0.01 <0.01
Balancing the risks of breastfeeding and formula feeding 40% 30% HIV Infection rate-breast-feeding Mortality rate-breastfeeding 12 months 6 months 14 wks 6 wks HIV Infection rate-formula feeding Mortality rate-formula feeding 24 months 20% 10% 0% Source: Nduati et al. JAMA 2000 Child age
Method of Infant Feeding and HIV Transmission in Breastfeeding Children Coutsoudis A. XIII AIDS Conf, July 40 2000, Durban S Africa (LbOr6) 36% % Transmission 30 20 10 8% 7% 7% 19%19% 26% 19% 25% 0 Infant Age Never Breastfed (N=157) Exclusive Breastfed (N=118) Mixed Feeding (N=276) 1 Day 6 Mos 15 Mos At 6 months: Exclusive vs Mixed: 0.6 (0.3-1.0) Exclusive vs Never: 1.2 (0.6-2.2)
Mortality in Breast- and Formula-Feeding Feeding HIV- Infected Women, Kenya Nduati R. XIII AIDS Conf, July 2000, Durban S Africa (WeOrC495) % Mortality 12 8 4 0 1.5% 0% 4.2% 0.5% 6.5% 1.7% 9.0% 2.3% 10.5% 6 Wks 6 Mos 12 Mos 18 Mos 24 Mos 3.8% Breastfeeding Formula Feeding RR Death (Breast vs Formula): 3.2 (95% CI 1.3-8.1%), p=0.01
New HIV infections and cumulative MTCT transmission rates by age and treatment group > 500 CD4 Age ZDV (N = 16 / 177) HIV Transm. Rate Placebo (N = 38 / 179) HIV Transm. Rate (No.) % Efficacy 95% CI 2 weeks 6.0 14.7 59% 12-81 6 weeks 7.7 19.3 60% 27-78 3 mos. 8.4 19.3 57% 23-76 6 mos. 8.8 19.2 54% 18-74 12 mos. 9.1 20.9 56% 24-75 18 mos. 24 mos. 9.1 22.0 59%* 28-76 * risk difference at 24 months = 12.7% (5.1-20.3%)
New HIV infections and cumulative MTCT transmission rates by age and treatment group < 500 CD4 Age ZDV (N = 50 / 137) HIV Transm. Rate Placebo (N = 55 / 136) HIV Transm. Rate (No.) % Efficacy 95% CI 2 weeks 20.1 26.1 23% -27-53 6 weeks 25.6 32.0 20% -18-46 3 mos. 27.5 34.3 20% -17-45 6 mos. 29.3 35.3 17% -19-42 12 mos. 38.5 38.0-1% -39-26 18 mos. 24 mos. 39.6 41.3 4%* -30-29 * risk difference at 24 months = 2.4% (-9.9-14.8%)
END